Guselkumab 在患有活动性银屑病关节炎轴性疾病的生物初治参与者中皮下给药的研究 (STAR)
一项 4 期、多中心、随机、双盲、安慰剂对照研究,评估 Guselkumab 在患有活动性银屑病关节炎轴性疾病的未接受过生物治疗的参与者中皮下给药的疗效和安全性
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
研究概览
详细说明
PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Frederiksberg、丹麦、2000
- Frederiksberg Hospital
-
Glostrup Municipality、丹麦、2600
- Rigshospitalet Glostrup
-
Køge、丹麦、4600
- Køge Sygehus Region Sjaelland
-
Vejle、丹麦、7100
- Vejle Sygehus
-
-
-
-
-
Cherkasy、乌克兰、18009
- Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council
-
Kharkiv、乌克兰、61204
- Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital
-
Khmelnytsky、乌克兰、29000
- Khmelnitckiy regional hospital
-
Kryvyi Rih、乌克兰、50056
- City Clinical Hospital No. 2
-
Kyiv、乌克兰、03049
- Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
-
Kyiv、乌克兰、03680
- SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine
-
Kyiv、乌克兰、02081
- Medical Center of 'Institute of Rheumatology', LLC
-
Lutsk、乌克兰、43005
- Volyn Regional Clinical Hospital
-
Odesa、乌克兰、65025
- Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
-
Poltava、乌克兰、36011
- ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
-
Ternopil、乌克兰、46002
- Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
-
Vinnytsia、乌克兰、21009
- Health Clinic Limited Liability Company
-
Zaporizhzhya、乌克兰、69600
- Medical Center LLC 'Modern Clinic'
-
-
-
-
-
Batumi、乔治亚州、6010
- Ltd Health Center
-
Kutaisi、乔治亚州、4600
- LTD Clinic LJ
-
Tbilisi、乔治亚州、0112
- LTD Helsicore
-
Tbilisi、乔治亚州、0102
- Aleksandre Aladashvili Clinic LLC
-
Tbilisi、乔治亚州、0141
- TSMU The First University Clinic
-
Tbilisi、乔治亚州、0179
- Clinic on Mtskheta Street
-
Tbilisi、乔治亚州、0186
- Consilium Medulla-multiprofile clinic Ltd
-
Tbilisi、乔治亚州、0160
- LTD MediClub Georgia
-
Tbilisi、乔治亚州、0180
- LTD The First Medical Center
-
Tbilisi、乔治亚州、0160
- LTD 'Aversi Clinic'
-
Tbilisi、乔治亚州、0102
- Ltd American Hospital Network
-
Tbilisi、乔治亚州、0159
- JSC K Eristavi National Center of experimental and Clinical surgery
-
Tbilisi、乔治亚州、0159
- Tbilisi Heart and Vascular Clinic Ltd
-
Tbilisi、乔治亚州、0114
- Ltd New Hospitals
-
Tnilisi、乔治亚州、0159
- JSC Evex Hospitals
-
-
-
-
-
Haifa、以色列、31048
- Bnai Zion Medical Center
-
Haifa、以色列、34362
- Carmel Medical Center
-
Holon、以色列、5822012
- Wolfson Medical Center
-
Kfar Saba、以色列、4428164
- Meir Medical Center
-
Ramat Gan、以色列、5265601
- Sheba Medical Center
-
-
-
-
-
Barnaul、俄罗斯、656038
- Altay Medical State University
-
Chelyabinsk、俄罗斯、454076
- Chelyabinck Regional Clinical Hospital
-
Chelyabinsk、俄罗斯、454092
- Chelyabinsk Regional Clinical Dermatovenerological Dispensary
-
Izhevsk、俄罗斯、426009
- Regional Clinical Diagnostic Center of Udmurtia Region
-
Kemerovo、俄罗斯、650070
- LLL Medical Center Revma-Med
-
Korolyov、俄罗斯、141060
- LLC Family Outpatient Clinic # 4
-
Krasnoyarsk、俄罗斯、660123
- Regional SBI of PH Krasnoyarsk Regional Clinical hospital #20 named after I.S. Berzon
-
Moscow、俄罗斯、115419
- Clinical-Diagnostic Center Euromedservice, JSC
-
Moscow、俄罗斯、115522
- FGBU Research Institute of Rheumatology named V.A.Nasonova
-
Moscow、俄罗斯、129110
- GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi'
-
Omsk、俄罗斯、644024
- Llc Ultramed
-
Orenburg、俄罗斯、460000
- GBOU VPO Orenburg State Medical University
-
Perm、俄罗斯、614990
- GBUZ Perm Regional Clinical Hospital
-
Petrozavodsk、俄罗斯、185019
- Republican Hospital n.a.V.A.Baranov
-
Rostov-on-Don、俄罗斯、344007
- Rostov Regional Clinical Dermatovenerological Dispensary
-
Saint Petersburg、俄罗斯、190068
- St. Petersburg GBUZ Clinical Reumatological Hospital 25
-
Saint Petersburg、俄罗斯、194156
- X7 Clinical Research Company Limited
-
Tolyatti、俄罗斯、445846
- GBUZ of Samara Region 'Tolyatti City Clinical Hospital 5'
-
Ufa、俄罗斯、450005
- Republican Clinical Hospital - G.G. Kuvatov
-
Yaroslavl、俄罗斯、150007
- Clinical Hospital #3
-
Yekaterinburg、俄罗斯、620102
- Sverdlovsk Regional Clinical Hospital N. 1
-
-
-
-
-
Pleven、保加利亚、5804
- UMHAT 'Dr. Georgi Stranski', EAD
-
Pleven、保加利亚、5803
- Exacta Medica
-
Plovdiv、保加利亚、4001
- UMHAT Kaspela
-
Plovdiv、保加利亚、4001
- Medical Center Unimed Plovdiv
-
Plovdiv、保加利亚、4002
- Medical Center Artmed
-
Sofia、保加利亚、1606
- Military Medical Academy
-
Sofia、保加利亚、1680
- DCC Convex EOOD
-
Sofia、保加利亚、1794
- Medical Centre Synexus
-
Sofia、保加利亚、1336
- MHAT 'Lyulin' EAD
-
Sofia、保加利亚、1612
- UMHAT St. Ivan Rilski
-
Sofia、保加利亚、1750
- ASIMP Rheumatology Centre St Irina EOOD
-
Sofia、保加利亚、1336
- University Multiprofile Hospital Sofiamed Sofia
-
Targovishte、保加利亚、7700
- DDC Sv. Ivan Rilski OOD
-
-
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E8
- Skin Care Centre
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1C 5B8
- Eastern Regional Health Authority St Clares Mercy Hospital
-
-
Ontario
-
Toronto、Ontario、加拿大、M5T 2S8
- Toronto Western Hospital
-
-
Quebec
-
Québec、Quebec、加拿大、G1V 3M7
- G R M O Groupe de recherche en maladies osseuses Inc
-
-
-
-
-
Budapest、匈牙利、1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest、匈牙利、1023
- Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
-
Budapest、匈牙利、H-1036
- Qualiclinic Kft
-
Gyula、匈牙利、5700
- Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
-
Hódmezővásárhely、匈牙利、6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kistarcsa、匈牙利、2143
- Kistarcsai Flor Ferenc Korhaz
-
Székesfehérvár、匈牙利、8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
-
Veszprém、匈牙利、8200
- Vital Medical Center Orvosi es Fogaszati Kozpont
-
-
-
-
-
Hsinchu、台湾、30059
- National Taiwan University Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taoyuan、台湾、33305
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01370
- Adana City Hospital
-
Ankara、土耳其(türkiye)、06800
- Ankara Bilkent City Hospital
-
Ankara、土耳其(türkiye)、6100
- Hacettepe University Medical Faculty
-
Ankara、土耳其(türkiye)、06010
- Gulhane Training and Research Hospital
-
Antalya、土耳其(türkiye)、7059
- Akdeniz University Medical Faculty
-
Bursa、土耳其(türkiye)、16059
- Uludag University Medical Faculty
-
Istanbul、土耳其(türkiye)、34098
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul、土耳其(türkiye)、34899
- Marmara University Medical Faculty
-
Konya、土耳其(türkiye)、42080
- Necmettin Erbakan University Meram Medical Faculty
-
-
-
-
-
Berlin、德国、10789
- ISA - Interdisciplinary Study Association GmbH
-
Hamburg、德国、20095
- Hamburger Rheuma Forschungszentrum II
-
Herne、德国、44649
- Rheumazentrum Ruhrgebiet
-
Ratingen、德国、40878
- Rheumazentrum Ratingen
-
-
-
-
-
Ancona、意大利、60126
- A.O. Universitaria Ospedali Riuniti di Ancona
-
Monserrato、意大利、09124
- Azienda Ospedaliero-Universitaria di Cagliari
-
Reggio Emilia、意大利、42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma、意大利、00133
- Policlinico Tor Vergata
-
Rozzano (MI)、意大利、20089
- Humanitas Hospital
-
Verona、意大利、37126
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Brno、捷克语、61141
- Revmaclinic
-
Brno、捷克语、63800
- Revmatologie s r o
-
Brno-Židenice、捷克语、615 00
- Revmacentrum MUDr Mostera s r o
-
Hlučín、捷克语、748 01
- L K N Arthrocentrum
-
Karvina Frystat、捷克语、73301
- Revimex Pro s r o
-
Ostrava、捷克语、70800
- MUDr Rosypalova s r o
-
Pardubice、捷克语、53002
- Arthrohelp S.R.O.
-
Prague、捷克语、128 00
- Revmatologicky ustav
-
Uherské Hradiště、捷克语、68601
- Medical Plus S R O
-
-
-
-
-
Martin、斯洛伐克、036 01
- Reumatologicka Ambulancia 1
-
Nové Mesto nad Váhom、斯洛伐克、91501
- Reumatologicka ambulancia
-
Piešťany、斯洛伐克、921 01
- Reumatologická ambulancia Thermium s.r.o.
-
Poprad、斯洛伐克、05801
- REUMAMED POPRAD, s.r.o.
-
Rimavská Sobota、斯洛伐克
- Reumex s.r.o
-
-
-
-
-
Bialystok、波兰、15 879
- ClinicMed Daniluk Nowak Spolka Komandytowa
-
Bydgoszcz、波兰、85 168
- Szpital Uniwersytecki nr 2 im dr Jana Biziela
-
Bytom、波兰、41 902
- Nzoz Bif Med
-
Elblag、波兰、82-300
- Centrum Kliniczno Badawcze
-
Elblag、波兰、82-300
- Ambulatorium sp. z o.o.
-
Krakow、波兰、30-002
- Malopolskie Badania Kliniczne Sp z o o
-
Krakow、波兰、31-513
- Centrum Medyczne Promed
-
Lodz、波兰、90-338
- Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
-
Lodz、波兰、90-265
- Dermed Centrum Medyczne Sp z o o
-
Lodz、波兰、91 363
- Centrum Medyczne AMED oddzial w Lodzi
-
Lublin、波兰、20 607
- Reumed Zespol Poradni Specjalistycznych Filia nr 1
-
Lublin、波兰、20-412
- Pro Life Medica Sp. z o.o.
-
Lublin、波兰、20 831
- Velocity Lublin
-
Nadarzyn、波兰、05-830
- NZOZ Lecznica MAK MED S C
-
Nowa Sól、波兰、67-100
- Twoja Przychodnia - Centrum Medyczne Nowa Sol
-
Poznan、波兰、60 324
- Twoja Przychodnia PCM
-
Poznan、波兰、60-446
- Reumedika s c Wieslawa Porawska Lukasz Porawski
-
Torun、波兰、87-100
- MICS Centrum Medyczne Torun
-
Warsaw、波兰、02-793
- ETG Warszawa
-
Warsaw、波兰、00-874
- MICS Centrum Medyczne Warszawa
-
Warsaw、波兰、02 637
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Warsaw、波兰、02-665
- Centrum Medyczne Reuma Park
-
Warsaw、波兰、02 118
- Rheuma Medicus Sp z o o
-
Warsaw、波兰、03 291
- Centrum Medyczne AMED Targowek
-
Wroclaw、波兰、51 685
- WroMedica I Bielicka A Strzalkowska s c
-
Świdnik、波兰、21 040
- Lubelskie Centrum Diagnostyczne
-
-
-
-
-
Bangkok、泰国、10400
- Phramongkutklao Hospital and Medical College
-
Bangkok、泰国、10400
- Ramathibodi Hospital Mahidol University
-
Chiang Mai、泰国、50200
- Chiang Mai University
-
-
-
-
-
Camberwell、澳大利亚、3124
- Emeritus Research
-
Hobart、澳大利亚、7000
- Southern Clinical Research
-
Liverpool、澳大利亚、2170
- Liverpool Hospital
-
Maroochydore、澳大利亚、4558
- Rheumatology Research Unit
-
Melbourne、澳大利亚、3128
- Eastern Health - Box Hill Hospital
-
Melbourne、澳大利亚、3053
- Skin Health Institute Inc.
-
-
-
-
-
Solna、瑞典、171 76
- Karolinska Universitetssjukhuset
-
Uppsala、瑞典、753 09
- Akademiska Sjukhuset
-
-
-
-
Arizona
-
Avondale、Arizona、美国、85392
- Arizona Arthritis and Rheumatology Research PLLC 1
-
Chandler、Arizona、美国、85225
- Arizona Arthritis & Rheumatology Research, PLLC
-
Mesa、Arizona、美国、85210
- Arizona Arthritis and Rheumatology Research PLLC
-
Phoenix、Arizona、美国、85032
- Arizona Arthritis Research, PLC.
-
Sun City、Arizona、美国、85351
- Arizona Arthritis and Rheumatology Associates
-
Tucson、Arizona、美国、85723
- Southern Arizona VA Healthcare System
-
-
Arkansas
-
Searcy、Arkansas、美国、72143
- Unity Health-White County Medical Center
-
-
California
-
Fontana、California、美国、92335
- Kaiser Permanent Medical Center
-
Huntington Beach、California、美国、92648
- Newport Huntington Medical Group
-
La Jolla、California、美国、92093
- University Of California San Diego
-
San Diego、California、美国、92128
- Rheumatology Center of San Diego
-
-
Connecticut
-
Danbury、Connecticut、美国、06810
- Clinical Research Center of Connecticut
-
-
Florida
-
Bay Pines、Florida、美国、33744
- Bay Pines VA Healthcare System
-
Plantation、Florida、美国、33324
- Integral Rheumatology And Immunology Specialists
-
Zephyrhills、Florida、美国、33542
- Florida Medical Clinic, P.A.
-
-
Illinois
-
Chicago、Illinois、美国、60640
- Great Lakes Clinical Trials
-
Rockford、Illinois、美国、61114
- OrthoIllinois
-
Willowbrook、Illinois、美国、60527
- Willow Rheumatology and Wellness
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- Johns Hopkins Bayview Medical
-
Hagerstown、Maryland、美国、21740
- Klein And Associates M D P A
-
-
Michigan
-
Saint Clair Shores、Michigan、美国、48081
- Clinical Research Institute of Michigan, LLC
-
-
Minnesota
-
Eagan、Minnesota、美国、55121
- St. Paul Rheumatology P A
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Kansas City Physician Partners
-
Springfield、Missouri、美国、65807
- Clinvest
-
-
Ohio
-
Vandalia、Ohio、美国、45377
- STAT Research, Inc.
-
-
Oregon
-
Portland、Oregon、美国、97239
- OHSU Rheumatology Clinic, Marquam Hill
-
-
Texas
-
Amarillo、Texas、美国、79124
- Amarillo Center for Clinical Research
-
Austin、Texas、美国、78731
- Austin Regional Clinic
-
Colleyville、Texas、美国、76034
- Precision Comprehensive Clinical Research Solutions
-
Corpus Christi、Texas、美国、78404
- Adriana Pop Moody MD Clinic PA
-
Fort Worth、Texas、美国、76109
- AARA Clinical Research Lone Star Arthritis and Rheumatology 1
-
Houston、Texas、美国、77030
- UT Physicians Center for Autoimmunity
-
Irving、Texas、美国、75039
- AARA Clinical Research Lone Star Arthritis and Rheumatology
-
Lubbock、Texas、美国、79424
- West Texas Clinical Research
-
Mesquite、Texas、美国、75150
- Southwest Rheumatology Research LLC
-
Red Oak、Texas、美国、75154
- Epic Medical Research
-
Tomball、Texas、美国、77375
- DM Clinical Research
-
-
Washington
-
Seattle、Washington、美国、98104
- Swedish Medical Center
-
-
-
-
-
Barnet、英国、EN5 3DJ
- Royal Free London NHS Foundation Trust
-
Bradford、英国、BD5 0NA
- St. Lukes Hospital
-
Coventry、英国、CV2 2DX
- University Hospital Coventry & Warwickshire NHS Trust
-
Leeds、英国、LS7 4SA
- Chapel Allerton Hospital
-
Manchester、英国、M13 9WL
- Central Manchester University Hospitals NHS Foundation Trust
-
Newcastle、英国、NE29 8NH
- North Tyneside General Hospital
-
Stoke-on-Trent、英国、ST6 7AG
- Haywood Hospital
-
-
-
-
-
Cebu City、菲律宾、6000
- Cebu Doctors' University Hospital
-
Davao City、菲律宾、8000
- Davao Doctors Hospital
-
Lipa、菲律宾、4217
- Lipa Medix Medical Hospital
-
Manila、菲律宾、1000
- Philippine General Hospital
-
Manila、菲律宾、1000
- ManilaMed Medical Center Manila
-
Quezon City、菲律宾、1112
- St. Luke's Medical Center
-
San Fernando City、菲律宾、2500
- Ilocos Training and Regional Medical Center
-
-
-
-
-
Braga、葡萄牙、4710-243
- Uls Braga - Hosp. Braga
-
Guarda、葡萄牙、6300-749
- Ulsg - Hosp. Sousa Martins
-
Lisbon、葡萄牙、1350-352
- Hosp. Cuf Tejo
-
Lisbon、葡萄牙、1649-035
- Uls Santa Maria - Hosp. Santa Maria
-
Lisbon、葡萄牙、1050 034
- Ipr Inst Port de Reumatologia
-
Lisbon、葡萄牙、1349-019
- Uls Lisboa Ocidental - Hosp. Egas Moniz
-
Ponte de Lima、葡萄牙、4990-041
- Ulsam - Hosp. Conde de Bertiandos
-
Porto、葡萄牙、4200 319
- Uls Sao Joao - Hosp. Sao Joao
-
-
-
-
-
A Coruña、西班牙、15006
- Hosp Univ A Coruna
-
Barakaldo、西班牙、48902
- Hosp. Univ. de Cruces
-
Barcelona、西班牙、08036
- Hosp Clinic de Barcelona
-
Bilbao、西班牙、48013
- Hosp. Univ. de Basurto
-
Córdoba、西班牙、14004
- Hosp Reina Sofia
-
Madrid、西班牙、28040
- Hosp. Clinico San Carlos
-
Málaga、西班牙、29009
- Hosp Regional Univ de Malaga
-
Sabadell、西班牙、8208
- Corporacio Sanitari Parc Tauli
-
Santiago de Compostela、西班牙、15702
- Clinica Gaias
-
Seville、西班牙、41009
- Hosp. Virgen Macarena
-
Seville、西班牙、41013
- Hosp. Quiron Sagrado Corazon
-
Valencia、西班牙、46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Buenos Aires、阿根廷、C1199ABB
- Hospital Italiano de Buenos Aires
-
Buenos Aires、阿根廷、C1417
- Centro Privado de Medicina Familiar
-
Buenos Aires、阿根廷、1428
- Cosultorios Reumatologógicos Pampa
-
La Plata、阿根廷、B1900
- Hospital Italiano La Plata
-
San Fernando、阿根廷、B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán、阿根廷、T4000AXL
- Centro Medico Privado de Reumatologia
-
-
-
-
-
Hong Kong、香港
- Prince Of Wales Hospital
-
-
-
-
-
Batu Caves、马来西亚、68100
- Hospital Selayang
-
George Town、马来西亚、10990
- Hospital Pulau Pinang
-
Johor Bahru、马来西亚、81100
- Hospital Sultan Ismail
-
Kuala Lumpur、马来西亚、59100
- University Malaya Medical Centre
-
Seremban、马来西亚、70300
- Hospital Tuanku Jaafar
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) criteria at screening
- Have active PsA as defined by: a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline and b) C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram/deciliter (mg/dL) at screening from the central laboratory, and despite previous non-biologic disease modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
- Have magnetic resonance imaging (MRI)-confirmed PsA axial disease (positive MRI spine and/or sacroiliac [SI] joints, shown by a Spondyloarthritis Research Consortium of Canada [SPARCC] score of >= 3 in either the spine or the sacroiliac joints)
- Have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4, and have a spinal pain score (on a visual analog scale [VAS]) of at least 4
- Have active plaque psoriasis, with at least 1 psoriatic plaque of >= 2 centimeter (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis
Exclusion Criteria:
- Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
- Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing spondylitis (AS)/non-radiographic-axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
- Has previously received any biologic treatment
- Has ever received a Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor
- Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group 1: Guselkumab and Placebo
Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind. |
Guselkumab will be administered as subcutaneous injection.
其他名称:
Matching placebo will be administered as subcutaneous injection. |
|
实验性的:Group 2: Guselkumab
Participants will receive guselkumab SC. |
Guselkumab will be administered as subcutaneous injection.
其他名称:
|
|
实验性的:Group 3: Placebo followed by Guselkumab
Participants will receive matching placebo and will cross over to receive guselkumab SC. |
Guselkumab will be administered as subcutaneous injection.
其他名称:
Matching placebo will be administered as subcutaneous injection. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24
大体时间:Baseline and Week 24
|
BASDAI is a self-assessment tool that consists of 6 questions relating to 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. First 5 items were scored on a 10 centimeter (cm) visual analog scale (VAS) ranging from 0 equals to (=) none to 10=very severe. Quantitative morning stiffness was scored on a 10 cm VAS ranging from 0=0 hours to 10=2 or more hours. 2 scores for qualitative and quantitative morning stiffness were averaged, and total BASDAI score was average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity. |
Baseline and Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP) at Week 24
大体时间:Baseline and Week 24
|
The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the C-reactive protein (CRP) value. Selected cut-offs for improvement scores are: a change greater than or equal to (>=) 1.1 units for "clinically important improvement" and a change >= 2.0 units for "major improvement. |
Baseline and Week 24
|
|
Change from Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 24
大体时间:Baseline and Week 24
|
DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (milligram/deciliter [mg/dL], value less than [<] lower limit of quantification [LLOQ] is considered equal to half of the value of LLOQ for numerical calculations), participant assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound. |
Baseline and Week 24
|
|
Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24
大体时间:Baseline and Week 24
|
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function. |
Baseline and Week 24
|
|
Percentage of Participants with Investigator's Global Assessment (IGA) 0/1 Response at Week 24 among Participants with >= 3% Body Surface Area (BSA) Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
大体时间:Week 24
|
Percentage of participants with IGA 0/1 response at week 24 among the participants with >= 3 percent (%) BSA psoriatic involvement and an IGA score of >= 2 (mild) at baseline will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given timepoint. Overall lesions are graded for induration, erythema, and scaling using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 24
|
|
Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Score for Magnetic Resonance Imaging (MRI) Sacroiliac (SI) Joints at Week 24
大体时间:Baseline and Week 24
|
Change from baseline in SPARCC score for MRI SI joints at week 24 among the participants with a positive MRI of the sacroiliac joints at baseline will be reported. SPARCC method focuses on the cartilaginous portion of the SI joint, and scores presence (score of 1) versus absence (score of 0) of bone marrow edema in each SI joint quadrant. |
Baseline and Week 24
|
|
Percentage of Participants who Achieve a >= 50 % Improvement from Baseline in BASDAI Score at Week 24
大体时间:Baseline and Week 24
|
Percentage of participants who achieve a >= 50 % improvement from baseline in BASDAI score at week 24 will be reported. |
Baseline and Week 24
|
|
Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24
大体时间:Week 24
|
Percentage of participants who achieve ASDAS clinically important improvement at week 24 will be reported. |
Week 24
|
|
Percentage of Participants who Achieve Ankylosing Spondylitis Activity Score (ASAS) 40 Response at Week 24
大体时间:Week 24
|
Percentage of participants who achieve ASAS 40 response at Week 24 will be reported. ASAS 40 defined as improvement from baseline of >= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Participant's global assessment (0 to 10 cm; 0=very well, 10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none, 10=very severe); no worsening at all from baseline in remaining domain. |
Week 24
|
|
Percentage of Participants who Achieve ASDAS Major Improvement at Week 24
大体时间:Week 24
|
Percentage of participants who achieve ASDAS major improvement at Week 24 will be reported. |
Week 24
|
|
Change from Baseline in SPARCC Score for MRI Spine at Week 24
大体时间:Baseline and Week 24
|
Change from baseline in SPARCC score for MRI spine at week 24 among the participants with a positive MRI of the spine at baseline will be reported. The SPARCC scoring system for the spine scores the 6 discovertebral units considered by the reader as the most abnormal, and then separately assesses each quadrant of 3 adjacent sagittal slices, with additional points for "depth" and high "intensity" of the lesion. |
Baseline and Week 24
|
|
Number of Participants with Adverse Events (AEs)
大体时间:Up to 60 weeks
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 60 weeks
|
|
Number of Participants with Serious Adverse Events (SAEs)
大体时间:Up to 60 weeks
|
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
Up to 60 weeks
|
|
Number of Participants with Reasonably Related AEs
大体时间:Up to 60 weeks
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 60 weeks
|
|
Number of Participants with AEs Leading to Discontinuation of Study Intervention
大体时间:Up to 60 weeks
|
Number of participants with AEs leading to discontinuation of study intervention will be reported. |
Up to 60 weeks
|
|
Number of Participants with Infections
大体时间:Up to 60 weeks
|
Number of participants with infections will be reported. |
Up to 60 weeks
|
|
Number of participants with Injection-Site Reactions
大体时间:Up to 60 weeks
|
Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site. |
Up to 60 weeks
|
|
Number of Participants with Laboratory Abnormalities (Chemistry, Hematology) by Maximum Toxicity (Common Terminology Criteria for Adverse Events [CTCAE 5.0]) Grades
大体时间:Up to 60 weeks
|
Number of participants with laboratory abnormalities (chemistry, hematology) by maximum toxicity (CTCAE 5.0) grades will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE. |
Up to 60 weeks
|
|
Serum Guselkumab Concentration Over Time
大体时间:Up to 60 weeks
|
Serum guselkumab concentration over time will be reported. |
Up to 60 weeks
|
|
Number of Participants with Antibodies to Guselkumab
大体时间:Up to 60 weeks
|
Number of participants with antibodies to guselkumab will be reported. |
Up to 60 weeks
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物和有用的链接
一般刊物
- Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Ostergaard M, Baraliakos X. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y.
- Kharouf F, Gladman DD. Advances in the management of psoriatic arthritis in adults. BMJ. 2024 Nov 21;387:e081860. doi: 10.1136/bmj-2024-081860.
- Baraliakos X, Bird P, Deodhar A, Gladman DD, Helliwell PS, Poddubnyy D, Kavanaugh A, Ostergaard M, Soriano ER, Tam LS, Chakravarty SD, Leibowitz E, Gong C, Adelakun O, Xu S, Fuerst T, Saeed N, Landewe R, Mease PJ. Associations Between Clinical Characteristics and Magnetic Resonance Imaging of the Sacroiliac Joints and Spine: Exploratory Analysis of the Phase 4, Randomized, Placebo-Controlled STAR Study. J Psoriasis Psoriatic Arthritis. 2026 Oct 18:24755303261494534. doi: 10.1177/24755303261494534. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CR109043
- 2021-000465-32 (EudraCT编号)
- CNTO1959PSA4002 (其他标识符:Janssen Research & Development, LLC)
- 2023-504716-15-00 (注册表标识符:EUCT number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.